Skip to Content

Lei Feng, M.S.

Principal Statistical Analyst

Degree

  • M.S., North Carolina State University, Raleigh, NC

Areas of Interest

  • Design and analysis of clinical trials
  • Survival analysis
  • Longitudinal analysis

Publications

Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 2012; 119(18): 4123-4128.

Ji Y, Feng L, Liu P, Shpall EJ, Kebriaei P, Champlin R, Berry D, Cooper LJN. Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size. Journal of Biopharmaceutical Statistics 2012; 22(6): 1206-1219.

Kim WY, Prudkin L, Feng L, Kim E, Hennessy B, Lee JS, Lee JJ, Glisson BS, Lippman SM, Wistuba II, Hong WK, Lee HY.  Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to the insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer 2012; 118(16): 3993-4003.

Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkins lymphomas. Leukemia & Lymphoma 2012; 53(1): 50-56.

Ayala-Ramirez M, Feng L, Rivera S, Habra MA, Rich T, Busaidy N, Perrier N, Waguespack S, Phan A, Patel S, Jimenez C. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from a large, single institutional experience. Cancer 2011; 118(11): 2804-2812.

Garvey PB, Salavati S, Feng L, Butler CE.  Perfusion-related complications are similar for DIEP and muscle-sparing free TRAM flaps harvested on medial or lateral deep inferior epigastric Artery branch perforators for breast reconstruction. Plastic and Reconstructive Surgery 2011; 128(6): 581e-9e.

Momoh AO, Yu P, Skoracki RJ, Liu S, Feng L, Hanasono MM. A prospective cohort study of fibula free flap donor-site morbidity in 157 consecutive patients. Plastic and Reconstructive Surgery 2011; 128(3): 714-720.

Garvey PB, Salavati S, Feng L, Butler CE. Abdominal donor-site outcomes for medial versus lateral deep inferior epigastric artery branch perforator harvest. Plastic and Reconstructive Surgery 2011; 127(6): 2198-2205.

Kim WY, Kim MJ, Moon H, Yuan P, Kim JS, Woo JK, Zhang G, Suh YA, Feng L, Behrens C, Van Pelt CS, Kang H, Lee JJ, Hong WK, Wistuba II, Lee HY. Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology 2011; 152(6): 2164-2173.

Kronowitz SJ, Lam C, Terefe W, Hunt KK, Kuerer HM, Valero V, Lance S, Robb GL, Feng L, Buchholz TA. A multidisciplinary protocol for planned skin-preserving delayed breast reconstruction for patients with locally advanced breast cancer requiring postmastectomy radiation therapy: 3-year follow-up. Plastic and Reconstructive Surgery 2011; 127(6): 2154-2166.

Garvey PB, Selber JC, Madewell JE, Bidaut L, Feng L, Yu P. A prospective study of preoperative computed tomographic angiography for head and neck reconstruction with anterolateral thigh flaps. Plastic and Reconstructive Surgery 2011; 127(4): 1505-1514.

Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. Journal of Clinical Endocrinology and Metabolism 2011; 96(3):717-725. 

Crosby MA, Dong W, Feng L, Kronowitz SJ. Effect of intraoperative saline fill volume on perioperative outcomes in tissue expander breast reconstruction. Plastic and Reconstructive Surgery 2011; 127(3): 1065-1072.

Baumann DP, Crosby MA, Selber JC, Garvey PB, Sacks JM, Adelman DM, Villa MT, Feng L, Robb GL. Optimal timing of delayed free lower abdominal flap breast reconstruction after postmastectomy radiation therapy. Plastic and Reconstructive Surgery 2011; 127(3): 1100-1106.

Crosby MA, Hanasono MM, Feng L, Butler CE. Outcomes of partial vaginal reconstruction with pedicled flaps following oncologic resection. Plastic and Reconstructive Surgery 2011; 127(2): 663-669.

Saintigny P, Zhang L, Fan YH, El-Naggar AK, Papadimitrakopoulou VA, Feng L, Lee JJ, Kim ES, Ki Hong W, Mao L. Gene expression profiling predicts the development of oral cancer. Cancer Prevention Research 2011; 4(2): 218-229.

Garvey PB, Phines LD, Feng L, Gu X, Butler CE. Reconstructive strategies for partial sacrectomy defects based on surgical outcomes. Plastic and Reconstructive Surgery 2011; 127(1): 190-199.

Van Leeuwen BL, Rosenkranz KM, Feng L, Bedrosian I, Hartmann K, Hunt KK, Kuerer HM, Ross M, Singletary SE, Babiera GV. The effect of under-treatment of breast cancer in women 80 years of age and older. Critical Reviews in Oncology/Hematology 2011; 79(3): 315-320.

Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 2010; 28(30): 4609-4615.

Liu ML, Feng L, Tang X, Guo S. Gene promoter hypermethylation in leukoplakia of the oral mucosa. Pathology and Laboratory Medicine International 2010; 2: 71-277.

Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, Feng L, Wang J, Holsinger FC, Yu D, Myers JN. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 2010; 29(14): 2047-2059.

Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan YH, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, Mao L. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prevention Research 2010; 3(7): 800-809.

Lee JJ, Feng L, Reshef, DS, Sabichi AL, Williams B, Rinsurongkawong W, Wistuba II, Lotan R, Lippman SM. Mortality in the randomized, controlled lung intergroup trial of isotretinoin. Cancer Prevention Research 2010; 3(6): 738-744.

Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong M, Saxman S, Kelaghan J, Bleyer A, Fisch MJ. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: A randomized phase III trial. Journal of the National Cancer Institute 2010; 102(12): 859-865.

Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver R, Rodriguez MA, Hagemeister, FB, Pro, B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. British Journal of Hematology 2010; 150(2): 200-208.

Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman S, Busaidy NL. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the MD Anderson experience. Journal of Clinical Endocrinology & Metabolism 2010; 95(6): 2588-2595.

Behrens C, Feng L, Kadara H, Kim HJ, Lee JJ, Mehran R, Hong WK, Lotan R, Wistuba I. Expression of interleukin-1 receptor-associated kinase-1 (IRAK-1) in non-small cell lung carcinoma and preneoplastic lesions. Clinical Cancer Research 2010; 16(1): 34-44.

William WN Jr., Uyeli J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of extensive small-cell lung carcinoma. Cancer 2010; 116(10): 2409-2415.

Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Raminder P, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: The M.D. Anderson cancer center experience. Clinical Breast Cancer Journal 2010; 10(1): 46-51.

Wang M, Delasalle K, Feng L, Thomas S, Giralt S, Qazilbash M, Handy B, Lee JJ, Alexanian R. CR represents an early index of potential long survival in multiple myeloma. Bone Marrow Transplantation 2010; 45(3): 498-504.

Sun M, Behren C, Feng L, Ozburn N, Tang X, Yin G, Komaki R, Varella-Garcia M, Hong WK, Aldape K, Wistuba I. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clinical Cancer Research 2009; 15(15): 4829-4837.

Kim WY, Jin Q, Oh SH, Kim ES, Yang YJ, Lee DH, Feng L, Behrens C, Prudkin L, Miller YE, Lee JJ, Lippman SM, Hong WK, Wistuba II, Lee HY. Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Research 2009; 69(18): 7439-7448.

Saintigny P, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan Y, Feng L, Lee JJ, Kim ES, Hong WK, Lippman SM, Mao L. DeltaNp63 overexpression, along and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clinical Cancer Research 2009; 15(19): 6284-6291.

Hanrahan EO, Kies MS, Glisson BS, Khuri FR, Feng L, Tran HT, Ginsberg LE, Truong MT, Hong WK, Kim ES. A phase II study of lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck. American Journal of Clinical Oncology 2009; 32(3): 274-279.

Srivastava G, Rana V, Wallace S, Taylor S, Debnam M, Feng L, Suki D, Karp D, Stewart D, Oh Y. Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients. Journal of Thoracic Oncology 2009; 4(3): 333-337.

Wheler J, Tsimberidou AM, Hong D, Daing A, Jackson T, Liu S, Feng L, Kurzrock R. Survival of patients in a phase I clinic: the M. D. Anderson Cancer Center experience. Cancer 2009; 115(5): 1091-1099.

Papadimitrakopoulou VA, Lee JJ, William WN Jr, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SM. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. Journal of Clinical Oncology 2009; 27(4): 599-604.

William WN Jr, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VA. High-dose fenretinide in oral leukoplakia. Cancer Prevention Research 2009; 2(1): 22-26.

Grubbs EG, Rafeeq S, Jimenez C, Feng L, Lee JE, Evans DB, Perrier ND. Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial? Surgery 2008; 144(6): 852-858; discussion 858-859.

Yendamuri S, Vaporciyan AA, Zaidi T, Feng L, Fernandez R, Bekele NB, Hofstetter WL, Jiang F, Mehran RJ, Rice DC, Spitz MR, Swisher SG, Walsh GL, Roth JA, Katz RL. 3p22.1 and 10q22.3 deletions detected by fluorescence in situ hybridization (FISH): A potential new tool for early detection of non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology 2008; 3(9): 979-984.

Rao R, Feng L, Kuerer HM, Singletary SE, Bedrosian I, Hunt KK, Ross MI, Hortobagyi GN, Feig BW, Ames FC, Babiera GV.  Timing of surgical intervention for the intact primary in stage IV breast cancer patients.  Annals of Surgical Oncology 2008; 15(6): 1696-1702.

Montenson MM, Evans DB, Lee JE, Hunter GJ, Shellingerhout D, Vu T, Edeiken BS, Feng L, Perrier ND. Parathyroid exploration in the reoperative neck: improved preoperative localization with 4D-computed tomography. Journal of the American College of Surgeons 2008; 206(5): 888-895.

Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CA, Helman JI, Du B, Yueh B, Boyle JO. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research 2008; 14(7): 2095-2101.

Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JN. Adjuvant high-dose interferon for cutaneous melanoma Is most beneficial for patients with early stage III disease. Cancer 2008; 112(9): 2030-2037.

Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituzimab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Annals of Oncology 2008; 19(3): 553-559.

Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L. Podoplanin: A novel marker for oral cancer risk in patients with oral premalignancy. Journal of Clinical Oncology 2008; 26(3): 354-360.

Nehete PN, Nehete BP, Hill L, Manuri PR, Baladandayuthapani V, Feng L, Simmons J, Sastry KJ. Selective induction of cell-mediated immunity and protection of rhesus macaques from chronic SHIVKU2 infection by prophylactic vaccination with a conserved HIV-1 envelope peptide-cocktail. Virology 2008; 370: 130-141.

Jin Q, Feng L, Behrens C, Bekele BN, Wistuba II, Hong WK, Lee HY. Implication of AMP-activated protein kinase and Aki-regulated survivin in lung cancer chemopreventive activities of deguelin. Cancer Research 2007; 67(24): 11630-11639.

Stava CJ, Beck ML, Feng L, Lopez A, Busaidy N, Vassilopoulou-Sellin R. Diabetes mellitus among cancer survivors. Journal of Cancer Survival 2007; 1(2): 108-115.

Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, Lotan R. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western array and immunohistochemistry.  Cancer Research 2006; 66(23): 11194-1206.

Rosenkranz KM, Bedrosian I, Feng L, Hunt KK, Hartman K, Lucci A, Meric-Bernstam F, Kuerer HM, Singletary ES, Hwang R, Feig B, Ross M, Ames F, Babiera GV.  Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. American Journal of Surgery 2006; 192(4): 541-544.

Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS.  Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. Journal of Clinical Oncology 2006; 24(25): 4163-4169.

Mullen JT, Feng L, Xing Y, Mansfield PF, Gershenwald JE, Lee JE, Ross MI, Cormier JN. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Annals of Surgical Oncology 2006; 13(7): 902-909.

Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MI. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 2006; 106(9): 2012-2020.

Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong WK.  Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. Journal of the National Cancer Institute 2006; 98(7): 441-450.

Tsimberidou A, Younes A, Romaguera J, Hagemeister FB, Rodriguez MA, Feng L, Ayala A, Smith T, Cabanillas F, McLaughlin P. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer 2005; 104: 345-353.

Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: Current status and future directions. Journal of Clinical Oncology 2005; 23(19): 4450-4457.

Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ, Ro JY, Feng L, Truong M, Yalamanchili A, Lopez-Berestein G, Hong WK, Khokhar AR, Shin DM. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 2005; 23(15): 3495-3501.

Lu C, Soria JC, Tang X, Xu XC, Wang L, Mao L, Lotan R, Kemp B, Bekele BN, Feng L, Hong WK, Khuri FR. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. Journal of Clinical Oncology 2004; 22(22): 4575-4583.

Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, Khuri FR, Mao L. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non–small-cell lung cancer. Journal of Clinical Oncology 2004; 22(16): 3230-3237.

Youssef EM, Lotan D, Issa JP, Wakasa K, Fan YH, Mao L, Hassan K, Feng L, Lee JJ, Lippman SM, Hong WK, Lotan R. Hypermethylation of the retinoic acid receptor-b2 gene in head and neck carcinogenesis. Clinical Cancer Research 2004; 10(5): 1733-1742.

Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clinical Lung Cancer 2003; 5(1): 40-45.

Soria JC, Moon C, Kemp BL, Liu DD, Feng L, Tang X, Chang YS, Mao L, Khuri FR. Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer. Clinical Cancer Research 2003; 9(5): 1785-1791.

Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E Jr, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers J, Clayman G, Hong WK. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002; 95: 322-330.

Khuri FR, Wu H, Lee JJ, Kemp BL, Lotan R, Lippman SM, Feng L, Hong WK,Xu XC. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clinical Cancer Research 2001; 7: 861-867.

Khuri FR, Lotan R, Kemp BL, Lippman SM, Wu H, Feng L, Lee JJ, Cooksley CS, Parr B, Chang E, Walsh GL, Lee JS, Hong WK, Xu XC. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. Journal of Clinical Oncology 2000; 18(15): 2798-2804.

Tea K, El-Naggar AK, Yoo E, Feng L, Lee JJ, Hong WK, Hittelman WN, Shin DM. Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis. Clinical Cancer Research 2000; 6: 2821-2828.

 

Updated March 6, 2013


© 2014 The University of Texas MD Anderson Cancer Center